{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T15:51:38Z","timestamp":1773330698945,"version":"3.50.1"},"reference-count":0,"publisher":"American Society for Microbiology","issue":"1","license":[{"start":{"date-parts":[[1976,7,1]],"date-time":"1976-07-01T00:00:00Z","timestamp":205027200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[1976,7]]},"abstract":"<jats:p>\n            The antimicrobial activity of flumequine (R-802) was characterized by in vitro and in vivo procedures. Assay of the minimal inhibitory concentrations for 321 recent clinical isolates revealed that 88% of the gram-negative bacteria were inhibited by an R-802 concentration of 6.2 \u03bcg\/ml or less. Cross-resistance in laboratory-derived mutants of\n            <jats:italic>Proteus vulgaris<\/jats:italic>\n            was essentially complete for R-802, nalidixic acid, and oxolinic acid, although quantitative differences were evident. R-802 was more effective than either of these quinolone antibacterials in preventing the development of experimental murine pyelonephritis (\n            <jats:italic>P. vulgaris<\/jats:italic>\n            ). R-802 and trimethoprim\/sulfamethoxazole (1:5) were equally effective in resolving a\n            <jats:italic>P. mirabilis<\/jats:italic>\n            -induced prostatitis of rats.\n          <\/jats:p>","DOI":"10.1128\/aac.10.1.20","type":"journal-article","created":{"date-parts":[[2012,6,27]],"date-time":"2012-06-27T23:57:02Z","timestamp":1340841422000},"page":"20-24","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":42,"title":["Bioevaluation of the Antibacterial Flumequine for Urinary Tract Use"],"prefix":"10.1128","volume":"10","author":[{"given":"S. R.","family":"Rohlfing","sequence":"first","affiliation":[{"name":"Riker Laboratories, Inc., St. Paul, Minnesota 55101"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. F.","family":"Gerster","sequence":"additional","affiliation":[{"name":"Riker Laboratories, Inc., St. Paul, Minnesota 55101"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. C.","family":"Kvam","sequence":"additional","affiliation":[{"name":"Riker Laboratories, Inc., St. Paul, Minnesota 55101"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.10.1.20","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.10.1.20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T13:34:40Z","timestamp":1645450480000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.10.1.20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1976,7]]},"references-count":0,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1976,7]]}},"alternative-id":["10.1128\/AAC.10.1.20"],"URL":"https:\/\/doi.org\/10.1128\/aac.10.1.20","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[1976,7]]},"assertion":[{"value":"1976-07-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}